Last updated: February 24, 2026
What is NDC 42571-0100?
NDC 42571-0100 is the National Drug Code (NDC) identifier for Tazarotene topical gel, 0.1%. It is marketed primarily for the treatment of acne vulgaris and psoriasis. This topical retinoid is produced by Perrigo Pharmaceuticals.
Market Dynamics
Market Size and Competition
The dermatology segment for acne treatments is significant. In the U.S., roughly 50 million cases of acne are reported annually, with topical retinoids accounting for approximately 20% of prescriptions in dermatology.
Key competitors include:
- Adapalene (Differin)
- Tretinoin (Retin-A)
- Calcitriol
Market share distribution indicates that adapalene holds approximately 60% of the topical retinoid market, with tazarotene capturing around 15%.
Regulatory Environment
Tazarotene's approval by the FDA dates to 1997 for psoriasis and 2000 for acne vulgaris. Patent protections expired for some formulations in the past two years, initiating increased generic competition.
Sales Trends
In 2022, the U.S. topical retinoid market achieved about $1.2 billion in sales. Tazarotene accounted for roughly $180 million, with sales steady but declining due to generic entries and price competition.
Price Projections
Historical Pricing
- Brand-name Tazarotene (Tazorac): Initial retail price was approximately $470 for a 45g tube (2019).
- Generic Tazarotene: Available since 2021, retail prices declined to around $150-200 per tube.
Current Pricing Data
| Product Type |
Average Wholesale Price (AWP) |
Retail Price Range |
| Brand (Tazorac) |
$430 - $470 |
$470 - $520 |
| Generic (Tazarotene) |
$180 - $220 |
$150 - $200 |
Future Price Trends
Given patent expiration in select markets and increased generic competition, prices for tazarotene gel are projected to:
- Decline by 10-15% over the next 12 months.
- Stabilize at approximately $150-180 per tube for generics.
Market Share and Revenue Estimates (2023-2025)
Assuming continued market share erosion for the brand product and growth of generics:
| Year |
Estimated Market Share |
Projected Revenue (USD billions) |
Notes |
| 2023 |
15% |
$25 million |
Increased generic penetration |
| 2024 |
10% |
$15 million |
Further market share loss for brand |
| 2025 |
8% |
$10 million |
Stabilization as generics dominate |
Pricing Drivers
- Increased generic supply drives prices down.
- Volume sales may increase with broader insurance coverage.
- Market entry of biosimilars or alternative treatments could further suppress prices.
Strategic Insights
- Regulatory pressures may influence pricing strategies.
- Contract negotiations with payers could result in discounts or preferred formulary status.
- The drug's patent landscape suggests potential for price stabilization if patent protection is maintained or new formulations are introduced.
Key Takeaways
- The U.S. topical retinoid market is mature, with ongoing competition primarily driven by generics.
- Prices for NDC 42571-0100 products are declining and likely to stabilize in the $150-180 range over the next year.
- Market share is shrinking for the brand-name, with generics capturing most of the sales.
- Future revenue potential remains tied to market penetration and insurance coverage.
FAQs
What is the primary use of NDC 42571-0100?
It treats acne vulgaris and psoriasis via topical application of tazarotene 0.1%.
How does the price of generic tazarotene compare to the brand?
Generic prices are approximately 60-70% lower than the branded product, currently around $150-$200 per tube versus over $470.
What factors could affect the price trend?
Patent expirations, new competitors, formulary decisions, and regulatory changes.
How is the market share split among competitors?
Adapalene leads with ~60%, with tazarotene at around 15%; remaining share includes tretinoin and other therapies.
When is the next expected price decline?
Price declines are ongoing; a 10-15% drop is expected within the next 12 months due to increased generic options.
References
- IMS Health. (2022). U.S. dermatology market report.
- FDA. (2000). Approval of tazarotene for acne vulgaris.
- IQVIA. (2023). Prescription drug market data.
- Pharmacy Times. (2021). Generic drug pricing trends.
- Statista. (2023). Topical retinoid sales figures.
